Assessing and Overcoming Resistance Phenomena against a Genetically Modified Vaccinia Virus in Selected Cancer Cell Lines
Open Access
- 14 October 2020
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21 (20), 7618
- https://doi.org/10.3390/ijms21207618
Abstract
Genetically modified vaccinia viruses (VACVs) have been shown to possess profound oncolytic capabilities. However, tumor cell resistance to VACVs may endanger broad clinical success. Using cell mass assays, viral replication studies, and fluorescence microscopy, we investigated primary resistance phenomena of cell lines of the NCI-60 tumor cell panel to GLV-1h94, a derivative of the Lister strain of VACV, which encodes the enzyme super cytosine deaminase (SCD) that converts the prodrug 5-fluorocytosine (5-FC) into the chemotherapeutic compound 5-fluorouracil (5-FU). After treatment with GLV-1h94 alone, only half of the cell lines were defined as highly susceptible to GLV-1h94-induced oncolysis. When adding 5-FC, 85% of the cell lines became highly susceptible to combinatorial treatment; none of the tested tumor cell lines exhibited a “high-grade resistance” pattern. Detailed investigation of the SCD prodrug system suggested that the cytotoxic effect of converted 5-FU is directed either against the cells or against the virus particles, depending on the balance between cell line-specific susceptibility to GLV-1h94-induced oncolysis and 5-FU sensitivity. The data provided by this work underline that cellular resistance against VACV-based virotherapy can be overcome by virus-encoded prodrug systems. Phase I/II clinical trials are recommended to further elucidate the enormous potential of this combination therapy.This publication has 32 references indexed in Scilit:
- Single-cycle viral gene expression, rather than progressive replication and oncolysis, is required for VSV therapy of B16 melanomaGene Therapy, 2009
- Oncolytic viruses: a novel form of immunotherapyExpert Review of Anticancer Therapy, 2008
- Targeted delivery of a suicide gene to human colorectal tumors by a conditionally replicating vaccinia virusGene Therapy, 2008
- Eradication of Solid Human Breast Tumors in Nude Mice with an Intravenously Injected Light-Emitting Oncolytic Vaccinia VirusCancer Research, 2007
- History of Oncolytic Viruses: Genesis to Genetic EngineeringMolecular Therapy, 2007
- The NCI60 human tumour cell line anticancer drug screenNature Reviews Cancer, 2006
- Mechanistic and Predictive Profiling of 5-Fluorouracil Resistance in Human Cancer CellsCancer Research, 2004
- Breast cancer-specific expression of the Candida albicans cytosine deaminase gene using a transcriptional targeting approachCancer Gene Therapy, 2000
- Concomitant expression ofE. colicytosine deaminase and uracil phosphoribosyltransferase improves the cytotoxicity of 5-fluorocytosineFEMS Microbiology Letters, 1998
- New Colorimetric Cytotoxicity Assay for Anticancer-Drug ScreeningJNCI Journal of the National Cancer Institute, 1990